Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor settles US Xopenex patent suit with Teva

This article was originally published in Scrip

Executive Summary

Sepracorhas settled a patent infringement suit withBarr Laboratories, now a part ofTeva Pharmaceutical Industries, in connection with the generics firm's ANDA for the short acting beta-agonist Xopenex (levalbuterol HCl inhalation solution), thus permitting Teva to launch generic levalbuterol in the US on February 17th, 2013, under a non-exclusive licence. Sepracor and Teva will ask the US District Court for the District of Delaware to dismiss their litigation.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel